Benzinga | May 25, 2021 09:07AM EDT

Bioventus Reports Human Placental Tissue Showed To Contain An Array Of Beneficial Growth Factors, Cytokines, Anti-Inflammatory Molecules

Demonstrated Significant Reduction of Pain and Cartilage Degeneration in Rat Osteoarthritis Model

DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, announced human placental tissue, prepared as a particulate composition, termed PTP-001, was shown to contain an array of beneficial growth factors, cytokines and anti-inflammatory molecules, which significantly reduced pain and cartilage degeneration in a rat osteoarthritis (OA) model. These findings were published on May 19, 2021 in Osteoarthritis and Cartilage available at https://www.oarsijournal.com/article/S1063-4584(21)00734-2/fulltext.

The in vivo activity of PTP001 on joint pain and histopathology was evaluated in a rat model of OA that was induced surgically by destabilization of the medial meniscus. In the model, PTP001 significantly reduced pain responses throughout six weeks postdosing as compared to a saline treatment. The magnitude and duration of pain reduction following a single intra-articular treatment with PTP001 was comparable to that observed for animals treated with a corticosteroid (active control). For rats that received two doses of PTP001, administered two weeks apart, significant reductions in cartilage degeneration scores were also observed.

"We believe that PTP001 represents a promising biologic candidate for osteoarthritis, with a multimodal potential mechanism of action that may contribute to symptom management and disease modification," said Carl Flannery Senior Director, Scientific Affairs, Bioventus. "We will continue with further research and development of PTP001, as we believe it represents a novel approach for the treatment of OA, and potentially other musculoskeletal conditions with unmet clinical need."

Authors of this study include: Carl R. Flannery, Ph.D., Bioventus; Scott A. Seaman, Ph.D., Bioventus; Kelly E. Buddin B.S., Bioventus; Michael A. Nasert, B.A., MTF Biologics; Eric J. Semler, Ph.D., MTF Biologics; Kathryn L. Kelley, B.S.; University of North Carolina, Chapel Hill; Marc Long, Ph.D., MTF Biologics; Jacob Favret, B.S., Bolder BioPATH; Alessandra Pavesio, M.S., Bioventus; and Richard F. Loeser, M.D., University of North Carolina, Chapel Hill.